Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

The novel anti-CD40 monoclonal antibody iscalimab has demonstrated clinical activity in patients with primary Sjögren's syndrome in a proof-of-concept study.

CD40 blockade shows therapeutic potential in Sjögren's syndrome

Cabozantinib plus ADT an effective combo in hormone-naïve metastatic prostate cancer

Cabozantinib plus androgen deprivation therapy (ADT) shows potent clinical activity in hormone-naïve metastatic prostate cancer (HNMPCa), according to the results of a phase II trial.

Cabozantinib plus ADT an effective combo in hormone-naïve metastatic prostate cancer

Steroid for hand OA: A potential short-term treatment option?

Short-term treatment (6 weeks) with 10 mg prednisolone effectively reduces finger pain and improves function in patients who have painful hand osteoarthritis (OA) coupled with signs of inflammation, the HOPE* study has shown.

Steroid for hand OA: A potential short-term treatment option?

How COVID-19 has changed our lives

The coronavirus has been spreading at a frantic pace, isolating families and snuffing out lives. As hunger and emotional contagion grip the nations, the hope of a containment also dims. No one has seen this enemy coming – the world has underestimated COVID-19.

How COVID-19 has changed our lives

Managing insomnia in primary care

Dr Poon Shi Hui, a consultant at the Department of Psychiatry at Singapore General Hospital, speaks to Roshini Claire Anthony on the different types of insomnia and the various management strategies deployed for each type.

Managing insomnia in primary care

Delgocitinib ointment safe, effective for moderate/severe atopic dermatitis

Treatment with delgocitinib 0.5% ointment leads to clinical improvements in adult patients with moderate-to-severe atopic dermatitis (AD) for up to 28 weeks, according to a Japan study.

Delgocitinib ointment safe, effective for moderate/severe atopic dermatitis

FLAIR confirms therapeutic potential of cabotegravir-rilpivirine in HIV

A long-acting (LA) injectable therapeutic regimen comprising the integrase strand-transfer inhibitor cabotegravir and the nonnucleoside reverse-transcriptase inhibitor rilpivirine shows therapeutic potential over an oral antiretroviral therapy (ART) regimen in adults with HIV-1, according to the week 96 results of the phase III FLAIR* trial.

FLAIR confirms therapeutic potential of cabotegravir-rilpivirine in HIV

Interferential current poised to become new treatment option for POI

Perineal interferential current (IC) proves beneficial in the treatment of women with premature ovarian insufficiency (POI) who are using systemic hormone therapy (HT) and presenting with sexual complaints, with the results of a 4-week trial showing that IC yields favourable effects on pain, lubrication, satisfaction and orgasm as compared with topical estriol.

Interferential current poised to become new treatment option for POI